Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once‐daily atorvastatin
- 12 December 2005
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 15 (2) , 115-121
- https://doi.org/10.1002/pds.1198
Abstract
Aims: Correct execution of prescribed dosing regimen(s) is essential for patients to benefit from lipid lowering treatments. The objective of this study was to estimate the effect of a pharmaceutical care program on the adherence of once‐daily atorvastatin treatment in patients with elevated cholesterol levels.Methods: In both linguistic regions of Belgium, two districts were randomized between usual care and a supportive intervention program. Eligible patients included hyperlipemic subjects taking atorvastatin for at least 3 months. ‘Adherence’ was defined as the proportion of days during which the electronic device record showed that the patient had taken the daily dose. ‘Persistence’ quantifies how long the treatment is executed.Results: A total of 392 patients from 35 pharmacies were included in the intent‐to‐treat (ITT) analysis of the data (194 patients received intervention and 198 in the control group). The intervention resulted in a 6.5% increase in post‐baseline adherence (p < 0.001) mainly driven by a 13% increase in persistence at 1 year (p = 0.002).Conclusion: A supportive pharmaceutical care program consisting of review by patient and pharmacist of each patient's electronically compiled dosing history, plus educational reminders, improves patient adherence to the once‐daily atorvastatin dosing regimen, mainly by extending persistence. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 8 references indexed in Scilit:
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialThe Lancet, 2003
- Long-term Persistence in Use of Statin Therapy in Elderly PatientsJAMA, 2002
- Estimating the Power of Compliance—Improving MethodsControlled Clinical Trials, 2000
- Predictors of Long-term Persistence on Statins in a Subsidized Clinical PopulationValue in Health, 2000
- Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary PreventionEuropean Heart Journal, 1998
- Learning versus confirming in clinical drug development*Clinical Pharmacology & Therapeutics, 1997
- How Often Is Medication Taken as Prescribed?JAMA, 1989
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984